Multimodal analysis identifies a fibroblast subtype enriched in EGFR-mutant NSCLC and its spatial niches
A mutation-specific stromal-tumor-immune regulatory network is revealed and the COL16A1-integrin β1 pathway is established as a rational therapeutic target to enhance the efficacy of osimertinib and pembrolizumab in EGFR -mutant NSCLC.